Dow Inc vs Tempus AI — how do they compare? Dow Inc trades at $30.35 (market cap $21.85B), while Tempus AI trades at $58.35 (market cap $10.54B). The key difference: Dow Inc is far larger — about 2.1× Tempus AI's market cap, and Dow Inc pays a 4.62% dividend while Tempus AI pays none. Which is the better fit depends on your goals.
| DOW | TEM | |
|---|---|---|
Market Cap | $21.85B | $10.54B |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $41.87 | $103.25 |
52-Week Low | $20.65 | $42.37 |
Enterprise Value | $37.62B | $11.21B |
Dividend Yield | 4.62% | — |
Signals from Pluang's Aura AI — not financial advice
DOW trades at $30.37, up 4.62% on the day, with a bullish technical signal from moving averages despite negative profitability metrics. The company reported a net loss of $2.62 billion for 2025, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights Dow's inclusion in discussions about materials stocks benefiting from oil price spikes, while cash flow trends show improved net cash generation in 2025.
The outlook is mixed: analyst consensus suggests 19% upside to the $36.11 price target, but high P/E of 75.93 and negative margins pose valuation risks. Key opportunities include dividend payments and earnings beats, while risks involve sustained profitability challenges and rising debt-to-asset ratios nearing 30%.
Tempus AI (TEM) trades at $55.93, down 3.95% on the day, with strong analyst support (61.5% buy ratings) and a $69.20 consensus price target. The stock shows bullish technical signals with support at $55 and resistance at $58, while fundamentals reveal robust revenue growth ($1.27B in 2025) but significant losses (-$245M net income). Recent news highlights the company's expanding AI healthcare data platform and FDA approvals driving investor optimism despite ongoing profitability challenges.
TEM presents a high-risk, high-reward opportunity with Wall Street bullish on its unique healthcare data moat and AI capabilities. The primary investment thesis centers on the company's positioning to dominate precision medicine, though shareholders face substantial execution risk amid persistent losses and negative cash flow from operations. Near-term catalysts include Q2 2026 earnings on July 30 and continued expansion of high-margin data services.
Trailing returns across standard periods
Latest headlines on both assets
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →